Repligen Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Olivier Loeillot
- Full Time Employees
- 2,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Building 1 Waltham MA United States of America 02453
- IPO Date
- Apr 29, 1986
- CIK
- 0000730272
- Website
- repligen.com
- Similar Companies
- Business
- Repligen Corporation is a global life sciences company specializing in the development and commercialization of bioprocessing technologies and systems designed to increase efficiencies in the manufacturing of biological drugs. Its core product portfolio includes upstream and downstream bioprocessing solutions such as tangential flow filtration systems (XCell ATF®, KrosFlo® TFDF®), chromatography systems (KRM® Chromatography System, OPUS® Pre-packed Columns), affinity resins (AVIPure® AAV Affinity Resins), fluid management technologies, process analytical technology (PAT) devices (CTech™ SoloVPE® PLUS System, CTech™ FlowVPE® PLUS System, MAVERICK®, MAVEN®, REBEL®), and cell culture supplements. The company serves a broad range of biologics including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA, and cell and gene therapies, targeting biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen operates globally with significant market presence in North America, Europe, and Asia-Pacific. Recent major developments include the acquisition of 908 Devices' desktop portfolio of four bioprocessing analytical devices—MAVERICK, MAVEN, REBEL, and ZipChip—for $70 million in cash, which enhances Repligen's process analytical technology offerings across the bioprocess workflow. In 2025, it launched the CTech™ SoloVPE® PLUS System, a UV-based variable pathlength technology device that supports advances in process analytics. Repligen also expanded its strategic footprint through a definitive agreement to acquire ARTeSYN BioSolutions, a manufacturer of innovative process technologies. Additionally, it has formed a partnership with Novasign to integrate AI-powered digital twins technology aimed at streamlining process development and enabling real-time predictive control in bioprocessing operations. The company reported a strong financial performance in 2025 with quarterly revenues exceeding $180 million and upward adjustments in full-year revenue guidance reflecting sustained double-digit growth across all franchises and geographies. Repligen's comprehensive offerings span filtration and fluid management, chromatography, process analytics, and biologic protein products, backed by expert installation and qualification services to optimize bioprocessing equipment. This portfolio diversification and strategic expansion underscore Repligen's position as a technology leader in the bioprocessing industry, supporting the development and manufacturing of biologic drugs globally.
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Q2 Earnings Call Highlights
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
American Capital Management Inc. Purchases 22,605 Shares of Repligen Corporation $RGEN
Repligen Corporation $RGEN Shares Purchased by First Trust Advisors LP
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Repligen Corporation (RGEN) M&A Call Transcript
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Repligen to Report Second Quarter 2026 Financial Results
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Adobe, American Airlines, Broadcom, First Solar, Meta Platforms, Shopify, Space-X, Ventas, Waste Managment, and More
A Look at Repligen Corp (RGEN) After 4.9% Gain -- GF Value $175.89 vs Price $145.23
Repligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells Investors